Pharma Journalist -

Taiho Pharmaceuticaland Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

SMi is proud to announce the 3rd Annual 3D Cell Culture conference is returning to London in just under two weeks’ time. Researchers globally are realizing the potential of 3D cell…
Read More...

Value has become a buzzword, but its importance cannot be overstated. How do we ensure its survival? The beauty of language lies in the fact that it is personal. The meaning of…
Read More...

Bridging the gap between innovation and access is Percival Barretto-Ko's top priority The way he tells it, Percival Barretto-Ko owes a lot to the profession of teaching. The…
Read More...

Novelion Therapeutics Inc. announced that its subsidiary, Aegerion Pharmaceuticals has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. for the…
Read More...

Taiho Pharmaceutical and Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Moderna, Inc., announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD)…
Read More...

The pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with…
Read More...

Building on last year’s success SMi Group are proud to present the 4th Pre-filled Syringes West Coast 2019 Conference and exhibition in CA, USA. Conference Overview: Pre-Filled…
Read More...